Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Axitinib
Drug ID BADD_D00193
Description Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).[L6676] Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.[L6676] Axitinib is an indazole derivative.[A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations.
Indications and Usage Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
Marketing Status approved; investigational
ATC Code L01EK01
DrugBank ID DB06626
KEGG ID D03218
MeSH ID D000077784
PubChem ID 6450551
TTD Drug ID D01ZRI
NDC Product Code 0069-0145; 54893-0032; 68554-0088; 63539-026; 82920-028; 0069-0151; 65344-0033; 63539-044; 54893-0043
UNII C9LVQ0YUXG
Synonyms Axitinib | AG 013736 | AG013736 | AG-013736 | Inlyta
Chemical Information
Molecular Formula C22H18N4OS
CAS Registry Number 319460-85-0
SMILES CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood alkaline phosphatase increased13.04.02.004--
Adverse event08.06.01.010--Not Available
Appetite disorder19.09.01.002; 14.03.01.0040.000246%Not Available
Brain neoplasm17.20.01.003; 16.30.01.0030.000112%Not Available
Cardiac disorder02.11.01.0030.002227%Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Feeding disorder19.09.01.003; 14.03.02.0030.001701%Not Available
Embolism24.01.01.009--
Gastrointestinal motility disorder07.02.03.0010.000112%Not Available
Inflammation10.02.01.089; 08.01.05.0070.000582%Not Available
Limb discomfort15.03.04.0140.001388%Not Available
Malnutrition14.03.02.0040.000224%Not Available
Mediastinal disorder22.09.03.001--Not Available
Motor dysfunction17.01.02.031; 15.05.06.0060.000168%Not Available
Neoplasm progression16.16.02.0050.053054%Not Available
Temperature regulation disorder05.03.04.013; 08.05.01.0040.000112%Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.037015%
Psychiatric symptom19.01.02.001--Not Available
Renal neoplasm16.08.03.001; 20.01.04.0040.000381%Not Available
Ill-defined disorder08.01.03.049--Not Available
Inner ear disorder04.04.02.002--Not Available
Vocal cord disorder22.04.01.0030.000168%Not Available
Blood disorder01.05.01.004--Not Available
Adverse drug reaction08.06.01.009--Not Available
Autoimmune disorder10.04.04.0030.000112%
Bone lesion15.02.04.0160.000302%Not Available
Disease progression08.01.03.0380.072048%
Diabetic nephropathy05.07.02.003; 20.05.03.011; 14.07.02.0030.000112%Not Available
Neoplasm recurrence16.16.02.0040.000168%Not Available
Food intolerance14.02.01.0050.000246%Not Available
The 14th Page    First    Pre   14 15 16 17    Next   Last    Total 17 Pages